BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 21863050)

  • 1. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.
    Lipkowitz S; Weissman AM
    Nat Rev Cancer; 2011 Aug; 11(9):629-43. PubMed ID: 21863050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of cancer stem cells by RING finger ubiquitin ligases.
    Kang B; Sun XH
    Stem Cell Investig; 2014; 1():5. PubMed ID: 27358852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase.
    Kamura T; Brower CS; Conaway RC; Conaway JW
    J Biol Chem; 2002 Aug; 277(33):30388-93. PubMed ID: 12048197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Elongin C and Skp1 sequences that determine Cullin selection.
    Yan Q; Kamura T; Cai Y; Jin J; Ivan M; Mushegian A; Conaway RC; Conaway JW
    J Biol Chem; 2004 Oct; 279(41):43019-26. PubMed ID: 15280393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent insight into the role of RING-finger E3 ligases in glioma.
    Cao Y; Zhou H; Chen X; Li Y; Hu J; Zhou G; Wang L
    Biochem Soc Trans; 2021 Feb; 49(1):519-529. PubMed ID: 33544148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma.
    Yin J; Zhu JM; Shen XZ
    Int J Cancer; 2015 Jan; 136(2):249-57. PubMed ID: 24420637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases.
    Zhou W; Wei W; Sun Y
    Cell Res; 2013 May; 23(5):599-619. PubMed ID: 23528706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34.
    Seol JH; Feldman RM; Zachariae W; Shevchenko A; Correll CC; Lyapina S; Chi Y; Galova M; Claypool J; Sandmeyer S; Nasmyth K; Deshaies RJ; Shevchenko A; Deshaies RJ
    Genes Dev; 1999 Jun; 13(12):1614-26. PubMed ID: 10385629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
    Jung YS; Qian Y; Chen X
    FEBS Lett; 2012 May; 586(10):1397-402. PubMed ID: 22673504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Following Ariadne's thread: a new perspective on RBR ubiquitin ligases.
    Wenzel DM; Klevit RE
    BMC Biol; 2012 Mar; 10():24. PubMed ID: 22420831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
    Soucy TA; Smith PG; Rolfe M
    Clin Cancer Res; 2009 Jun; 15(12):3912-6. PubMed ID: 19509147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation.
    Magnifico A; Ettenberg S; Yang C; Mariano J; Tiwari S; Fang S; Lipkowitz S; Weissman AM
    J Biol Chem; 2003 Oct; 278(44):43169-77. PubMed ID: 12907674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
    Liu L; Wong CC; Gong B; Yu J
    Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The APC11 RING-H2 finger mediates E2-dependent ubiquitination.
    Leverson JD; Joazeiro CA; Page AM; Huang Hk; Hieter P; Hunter T
    Mol Biol Cell; 2000 Jul; 11(7):2315-25. PubMed ID: 10888670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting E3 ubiquitin ligases for cancer therapy.
    Sun Y
    Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination.
    Metzger MB; Pruneda JN; Klevit RE; Weissman AM
    Biochim Biophys Acta; 2014 Jan; 1843(1):47-60. PubMed ID: 23747565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cullin-RING Ligases as attractive anti-cancer targets.
    Zhao Y; Sun Y
    Curr Pharm Des; 2013; 19(18):3215-25. PubMed ID: 23151137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitin ligases in oncogenic transformation and cancer therapy.
    Senft D; Qi J; Ronai ZA
    Nat Rev Cancer; 2018 Feb; 18(2):69-88. PubMed ID: 29242641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of ubiquitin ligase dynamics by the nucleolus.
    Mekhail K; Khacho M; Carrigan A; Hache RR; Gunaratnam L; Lee S
    J Cell Biol; 2005 Aug; 170(5):733-44. PubMed ID: 16129783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HECT family of E3 ubiquitin ligases: multiple players in cancer development.
    Bernassola F; Karin M; Ciechanover A; Melino G
    Cancer Cell; 2008 Jul; 14(1):10-21. PubMed ID: 18598940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.